Analysts Expect Caladrius Biosciences Inc (CLBS) Will Announce Earnings of -$0.44 Per Share
Equities analysts predict that Caladrius Biosciences Inc (NASDAQ:CLBS) will post earnings of ($0.44) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Caladrius Biosciences’ earnings. Caladrius Biosciences posted earnings per share of ($0.42) during the same quarter last year, which suggests a negative year over year growth rate of 4.8%. The business is scheduled to report its next earnings report on Thursday, August 8th.
On average, analysts expect that Caladrius Biosciences will report full year earnings of ($1.65) per share for the current year, with EPS estimates ranging from ($1.88) to ($1.33). For the next year, analysts expect that the business will report earnings of ($1.10) per share, with EPS estimates ranging from ($1.90) to ($0.69). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Caladrius Biosciences.
Caladrius Biosciences (NASDAQ:CLBS) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.05).
CLBS traded down $0.02 during trading on Tuesday, hitting $2.90. 11,926 shares of the company traded hands, compared to its average volume of 28,188. Caladrius Biosciences has a 1 year low of $2.77 and a 1 year high of $11.65.
Large investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its position in shares of Caladrius Biosciences by 42.9% during the 3rd quarter. Renaissance Technologies LLC now owns 280,864 shares of the biotechnology company’s stock valued at $1,657,000 after purchasing an additional 84,301 shares in the last quarter. Vanguard Group Inc grew its position in shares of Caladrius Biosciences by 2.9% during the 3rd quarter. Vanguard Group Inc now owns 202,568 shares of the biotechnology company’s stock valued at $1,196,000 after purchasing an additional 5,700 shares in the last quarter. Wesbanco Bank Inc. purchased a new position in shares of Caladrius Biosciences during the 1st quarter valued at $36,000. Morgan Stanley grew its position in shares of Caladrius Biosciences by 218.6% during the 1st quarter. Morgan Stanley now owns 6,996 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 4,800 shares in the last quarter. Finally, Summit Trail Advisors LLC purchased a new position in shares of Caladrius Biosciences during the 1st quarter valued at $64,000. 7.59% of the stock is owned by institutional investors and hedge funds.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Featured Article: Quiet Period Expirations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.